Table 3.
Disease-Free Survival of Patients With Endometrial Cancer.a
| Characteristic | No. | 5-year (%) | Univariate |
Multivariate |
||
|---|---|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |||
| Age | <.001 | .074 | ||||
| <60 | 537 | 83.7% | 1 | 1 | ||
| ≥60 | 177 | 69.2% | 2.29 (1.52-3.46) | 1.65 (0.95-2.84) | ||
| Ethnicity | .026 | .81 | ||||
| Non-Hispanic | 234 | 72.6% | 1 | 1 | ||
| Hispanic | 480 | 83.5% | 0.63 (0.42-0.95) | 0.94 (0.57-1.54) | ||
| BMI (kg/m2) | .044 | .27 | ||||
| <30 | 218 | 76.0% | 1 | 1 | ||
| ≥30 | 490 | 82.6% | 0.66 (0.44-0.99) | 1.34 (0.80-2.26) | ||
| Hypertension | .77 | .52 | ||||
| No | 320 | 78.8% | 1 | 1 | ||
| Yes | 394 | 81.8% | 0.94 (0.63-1.40) | 1.21 (0.67-2.18) | ||
| β-Blocker use | .62 | .77 | ||||
| No | 585 | 79.6% | 1 | 1 | ||
| Yes | 129 | 83.9% | 0.88 (0.52-1.48) | 1.10 (0.59-2.03) | ||
| Diabetes mellitus | .33 | .22 | ||||
| No | 484 | 78.9% | 1 | 1 | ||
| Yes | 230 | 83.9% | 0.81 (0.52-1.25) | 1.59 (0.76-3.36) | ||
| Metformin use | .19 | .47 | ||||
| No | 546 | 78.9% | 1 | 1 | ||
| Yes | 168 | 85.1% | 0.72 (0.44-1.18) | 0.74 (0.33-1.65) | ||
| Hypercholesterolemia | .83 | .94 | ||||
| No | 537 | 79.0% | 1 | 1 | ||
| Yes | 176 | 83.8% | 0.95 (0.61-1.50) | 0.97 (0.53-1.81) | ||
| Statin use | .24 | .62 | ||||
| No | 576 | 78.8% | 1 | 1 | ||
| Yes | 138 | 86.1% | 0.73 (0.43-1.24) | 1.22 (0.57-2.61) | ||
| NAFLD | <.001 | .034 | ||||
| No | 533 | 75.3% | 1 | 1 | ||
| Yes | 181 | 91.8% | 0.29 (0.16-0.51) | 0.46 (0.23-0.94) | ||
| CA-125 (IU/L) | <.001 | <.001 | ||||
| <35 | 457 | 91.5% | 1 | 1 | ||
| ≥35 | 177 | 54.9% | 6.09 (3.86-9.59) | 2.79 (1.62-4.81) | ||
| Platelet count (× 109/L) | <.001 | .56 | ||||
| <400 | 590 | 85.4% | 1 | 1 | ||
| ≥400 | 79 | 61.6% | 3.36 (2.12-5.35) | 0.86 (0.50-1.45) | ||
| Histology subtype | <.001 | .011 | ||||
| Endometrioid | 591 | 87.6% | 1 | 1 | ||
| Nonendometrioid | 123 | 49.3% | 5.69 (3.83-8.44) | 1.98 (1.17-3.37) | ||
| Grade | <0.001 | 0.013 | ||||
| 1-2 | 550 | 88.7% | 1 | 1 | ||
| 3 | 164 | 54.4% | 6.10 (4.08-9.13) | 2.12 (1.18-3.83) | ||
| Stage | <.001 | <.001 | ||||
| I-II | 554 | 92.3% | 1 | 1 | ||
| III-IV | 160 | 46.9% | 10.1 (6.48-15.7) | 4.93 (2.62-9.28) | ||
| VTE | <.001 | <.001 | ||||
| No | 657 | 86.6% | 1 | 1 | ||
| Yes | 57 | 19.5% | 10.2 (6.69-15.4) | 3.57 (2.01-6.36) | ||
Abbreviations: BMI, body mass index; CA, cancer antigen; CI, confidence interval; HR, hazard ratio; NAFLD, nonalcoholic fatty liver disease; VTE, venous thromboembolism; 5-yr (%), 5-year survival proportion.
a
Multivariate analysis with Cox proportional hazards regression test for P values. Significant P values are emboldened.